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Background: HPV is related to a number of cancer types, causing a considerable burden in both genders in
Europe. Female vaccination programs can substantially reduce the incidence of HPV-related diseases in women
and, to some extent, men through herd immunity. The objective was to estimate the incremental benefit of
vaccinating boys and girls using the quadrivalent HPV vaccine in Europe versus girls-only vaccination. Incremental
benefits in terms of reduction in the incidence of HPV 6, 11, 16 and 18-related diseases (including cervical, vaginal,
vulvar, anal, penile, and head and neck carcinomas and genital warts) were assessed.
Methods: The analysis was performed using a model constructed in MicrosoftWExcel, based on a
previously-published dynamic transmission model of HPV vaccination and published European epidemiological data
on incidence of HPV-related diseases. The incremental benefits of vaccinating 12-year old girls and boys versus
girls-only vaccination was assessed (70% vaccine coverage were assumed for both). Sensitivity analyses around
vaccine coverage and duration of protection were performed.
Results: Compared with screening alone, girls-only vaccination led to 84% reduction in HPV 16/18-related
carcinomas in females and a 61% reduction in males. Vaccination of girls and boys led to a 90% reduction in HPV
16/18-related carcinomas in females and 86% reduction in males versus screening alone. Relative to a girls-only
program, vaccination of girls and boys led to a reduction in female and male HPV-related carcinomas of 40% and
65%, respectively and a reduction in the incidence of HPV 6/11-related genital warts of 58% for females and 71%
for males versus girls-only vaccination.
Conclusions: In Europe, the vaccination of 12-year old boys and girls against HPV 6, 11, 16 and 18 would be
associated with substantial additional clinical benefits in terms of reduced incidence of HPV-related genital warts
and carcinomas versus girls-only vaccination. The incremental benefits of adding boys vaccination are highly
dependent on coverage in girls. Therefore, further analyses should be performed taking into account the
country-specific situation. In addition to clinical benefits, substantial economic benefits are also anticipated and
warrant further investigation as do the social and ethical implications of including boys in vaccination programs.
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The human papillomavirus (HPV), in particular subtypes
6, 11, 16 and 18 are responsible for a number of condi-
tions including genital warts, recurrent respiratory papil-
lomatosis, a subset of head and neck cancers as well as
vaginal, vulvar, cervical and anal cancers in females and
penile and anal cancers in males. There is a wealth of
published literature relating to reductions in the clinical* Correspondence: rmarty@hevaweb.com
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reproduction in any medium, provided the orand economic burden of cervical cancer, due in part to
the success of pap screening programs and the introduc-
tion of the HPV vaccines. This has meant that the
burden of other HPV-related cancers, particularly those
occurring in males, is often overshadowed and as such is
less well characterized [1]. In particular, data from a
recent meta-analysis by De Vuyst et al. report that 40.4%
of vulvar carcinomas, 69.9% of vaginal carcinomas and
84.3% of anal carcinomas are due to HPV (all subtypes)
[2]. Additionally, around 22% of head and neck cancers
test positive for HPV [3] and around 50% of peniletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Moreover, it is estimated that approximately 30% of all
HPV-related cancers occur in males, which in European
males corresponds to approximately 17,000 cancer cases
per year, of which over 15,000 are attributable to HPV 16.
The burden of HPV-related non-cervical cancers is, in
many settings, comparable to or greater than that asso-
ciated with cervical cancer. For example, in France the
total cost (2006/2007 EUR) of HPV-related cancers was
EUR 240 million, of which only EUR 84 million was at-
tributable to invasive cervical cancer [5]. Furthermore,
whilst the clinical and economic burden associated with
cervical cancer has declined notably in recent years, and
is likely to decline even more in the coming decades
owing to the introduction of the bivalent and quadriva-
lent HPV vaccines, the situation in relation to other
HPV-related cancers is less well characterized. Epi-
demiological data from the UK has suggested that the
age-standardized incidence of vulvar and vaginal cancer
in females and penile cancer in males has remained rela-
tively unchanged since the 1960s, but that the incidence
of anal cancer has increased substantially in both males
and females over the same time period [6]. Additionally,
a number of European studies have shown that the inci-
dence of HPV-related head and neck cancers in men has
been increasing in recent decades [7,8].
In addition to HPV-related cancer, HPV 6 and 11 are
responsible for 90% of cases of genital warts, which are
in turn responsible for an estimated 9–10% of all visits
to sexual health clinics [9,10]. Moreover, analysis of tem-
poral trends in a number of settings has shown that the
incidence of new cases of genital warts has increased
substantially in the past few decades, [11] such that each
year in Europe an estimated 287,000 to 326,000 cases of
HPV 6/11-related genital warts are reported in males
[1]. In terms of economic burden, a US based study by
Hoy et al. reported that in 2004 the direct costs of geni-
tal warts were USD 104 million for females and USD
119 million for males [12]. Similarly, in France the esti-
mated treatment cost per episode (direct medical costs,
societal perspective) of genital warts is EUR 483 (2005
EUR), leading to a total annual burden of EUR 23
million, which is just under half of the total annual man-
agement costs associated with cervical cancer in France
[13]. Genital warts also have a negative impact on qua-
lity of life and are associated with indirect costs with
Castellsague et al. reporting that 16.7% of patients had
used using sick leave due to genital warts [14,15].
Two vaccines exist that provide protection against
HPV-related diseases, a bivalent vaccine that provides
protection against HPV 16 and 18 and a quadrivalent
vaccine that provides protection against HPV 6, 11, 16
and 18. Although HPV vaccination was first approved
for use in females, the quadrivalent vaccine hassubsequently demonstrated efficacy in terms of prevent-
ing HPV-related disease in males and is approved and
recommended for use in males in both the US and
Australia for the prevention of anal cancer, anal intrae-
pithelial neoplasia and genital warts. In a 2011 study in
over 4,000 males aged 16–26 years, the efficacy of the
quadrivalent vaccine against HPV 6, 11, 16 or 18-related
external genital lesions was 92.4% among heterosexual
men and 79.0% among men who had sex with men.
Moreover, no HPV 16/18-related lesions were reported
in the vaccine group (a total of 3 HPV 16/18-related
lesions were reported in the placebo group) [16].
A large number of cost-effectiveness analyses con-
ducted in a number of different settings have shown that
vaccination of females is cost-effective in comparison
with no vaccination; however, there are relatively few
data relating to the incremental benefits of vaccinating
both males and females in comparison with female only
vaccination programs. The consensus among the few
studies that have been conducted is that gender-neutral
vaccination programs are likely to further reduce the in-
cidence of HPV-related disease in both males and
females [17,18]. For example, the findings of Brisson
et al. indicated that a gender-neutral vaccination pro-
gram (vaccinating 12-year old boys and girls) would re-
sult in an incremental reduction in the incidence of
HPV 16/18 infection of 16% in females and 23% in males
versus female only vaccination over a 70 year-long
period (assuming a 99% vaccine efficacy, 20-year long
duration of protection and 70% vaccine coverage) [19].
On a population level, the effectiveness of vaccination
programs has been shown to be dependent on uptake
rates and national strategies in relation to vaccination
vary between settings. Organized school-based vacci-
nation programs have a very high uptake in the target
population, although only 13% of young women in the
European Union are covered by such programs. In set-
tings where vaccination is provided on demand (e.g.
Germany and France) vaccination rates are approxi-
mately 50% [20]. Introducing policies to increase vaccine
uptake rate among girls would likely lead to a greater
reduction in the incidence of HPV-related disease. Alter-
natively, vaccinating both boys and girls could also lead
to reduced incidence of HPV-related disease amongst
both males and females. A recent analysis by Bogaards
et al. suggested that increasing vaccine coverage among
girls was a more effective strategy in terms of reducing
overall rates of HPV infection than vaccinating boys
[21]. As such, in the current exploratory analysis the
long-term clinical impact of vaccinating both boys and
girls is investigated in the European setting. In particular,
the impact of girls-only versus girls and boys vaccination
on the incidence of male HPV-related disease (anal,
penile and head and neck carcinoma and genital warts)
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well as uptake rates vary across Europe it should be
noted that the current analysis provides a mean estimate
only across Europe and country-specific analyses are
required for more accurate estimates of the incremental
benefits of vaccination of both girls and boys against
HPV 6, 11, 16 and 18.
Methods
Model structure
Epidemiological estimates for HPV-related disease were
based mainly on a previously published dynamic transmis-
sion model (a detailed description of which is provided by
Elbasha et al. [22] and Dasbach et al. [23]). In summary,
Elbasha et al. constructed a population dynamic model to
account for both the direct and indirect effects of vacci-
nation. Within the model, the population is divided into
groups based on age and gender, which allows the patterns
of HPV transmission among sexually active groups to be
modeled accurately. Structurally, the model can be consi-
dered as containing three key components: HPV transmi-
ssion, cervical cancer development and the occurrence of
genital warts. Our analysis was performed based on a two-
stage calculation. As a first stage, the US-based dynamic
transmission model of Elbasha et al. was run for each
vaccination strategy assessed (in this instance 12-year old
girls-only vaccination program and a 12-year old girls and
boys vaccination program). A screening only scenario was
also run, which provided a common baseline comparator.
The dynamic transmission model outputs absolute inci-
dence of HPV-related disease cases per year and is run
over a 100-year time span for each of the two vaccination
strategies.
In the second stage, the annual proportional reduc-
tions in disease incidence due to a given vaccination
strategy versus baseline scenario (screening only) were
derived for each HPV-related disease within Microsoft
Excel 2003. These proportional reductions were then ap-
plied to European incidence data reflecting incidences
prior to HPV vaccination implementation. The present
analysis is then able to derive avoided outcomes (i.e.
cases of HPV-related diseases avoided) versus screening
only for both the 12-year old girls-only vaccination pro-
gram and the 12-year old girls and boys (gender neutral)
vaccination program. The difference between the girls-
only and gender-neutral vaccination is also presented.
Internal validation of this two-step procedure was achieved
by being able to replicate US and UK results from Dasbach
et al. 2008 [23] and Elbasha et al. 2010 [17].
Model input data
The analysis incorporated female-specific conditions in-
cluding HPV 6/11/16/18 related cervical, vulvar and
vaginal intraepithelial neoplasia states and carcinoma,penile intraepithelial neoplasia and carcinoma in males
and genital warts, anal intraepithelial neoplasia and car-
cinoma, and head and neck cancers in both males and
females.
Epidemiological input data relating to the incidence of
HPV-related disease in Europe were derived from previ-
ously published epidemiologic studies by Bonnani et al.
[20] and Hartwig et al. [1] (Table 1). In line with these
sources, the definition of Europe within our analysis
encompasses a total of twenty six countries including all
European Union countries (except Greece, Hungary,
Luxemburg, and Romania) as well as three countries
(Iceland, Norway and Switzerland) outside the European
Union.
Vaccine efficacy for transient and persistent infections
and compliance input data used were derived from a
previously published model [17] and are described in
Table 1 and Table 2.
Assumptions
The vaccine (both for the girls-only and boys and girls
vaccination programs) was assumed to be administered
to 12-year olds. A number of assumptions were made
with regard to the vaccine coverage, compliance and
duration of vaccine protection (Table 3). A vaccine
coverage of 70% was assumed for girls in the girls-only
vaccination program and for both genders in the
gender-neutral vaccination program. Both vaccination
program strategies were assumed to achieve 70% cove-
rage rate starting from the first year of implementation
(no transition period was assumed). This figure repre-
sents the proportion of either girls or boys that received
at least one vaccination dose out of the full three doses
vaccination course. Imperfect adherence to the sched-
uled vaccination course was also taken into account
in line with the previously published analysis of
Elbasha and Dasbach (Table 3) [17]. Decreased vaccine
efficacy was also assumed for those having received
either one or two doses in comparison with those
who were fully vaccinated (three doses) (Table 2). In
base case, duration of vaccine protection was that of
patient lifetimes.
Apart from vaccination-related parameters, all US and
disease-specific parameters related to underlying demo-
graphic US population (pyramidal structure of age),
HPV transmission and progression to disease, cervical
and vaginal screening programs were assumed to be ap-
plicable to European settings [17].
External validation
The use of US-based input parameters for application in
the European setting seems reasonable when comparing
vaccination impact at different points in time, in terms
of cervical cancer incidence, published either with the
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aIn total 26 countries were considered in the analysis for incidence estimates, i.e. all European Union countries (except Greece, Hungary, Luxembourg, and
Romania). Three countries outside the European Union were included (Iceland, Norway and Switzerland).
bincludes several ICD 10 codes related sites (i.e., tongue, gum of the mouth, floor of the mouth, palate, tonsil, piriform sinus), hypopharynx and larynx sites.
Marty et al. BMC Cancer 2013, 13:10 Page 4 of 12
http://www.biomedcentral.com/1471-2407/13/10US base case model (Elbasha et al. 2007 [22]) or its
adaptation for the UK setting (Dasbach et al. 2008 [23]).
Components of the model that were modified for the
UK included the demographic characteristics (e.g.
mortality), screening, and treatment as well as clinical
and behavioral (i.e. sexual mixing) input parameters
(Dasbach et al. 2008 [23]). The UK model predicted a
relative reduction of cervical cancer of 42.4%, 76.7%,Table 2 Vaccine efficacy parameters and assumptions
Gender Male
HPV genotype 6 11 16
Against transient infection†,‡
- Cervical, vaginal & vulvar diseases ― ― 41.
- Genital warts & HPV 6, 11 49.0 57.0 ―
Against persistent infection
- Anal disease ― ― 78.
- Cervical, vaginal & vulvar diseases ― ― ―
- Penile disease ― ― 78.
Against individual diseases
- Genital warts 84.3 90.9 ―
Unit: percentage. Values were derived from [17].
†Efficacy against genital infection in males is assumed to prevent transmission of ge
‡Efficacy for 1 and 2 doses assumed to be 23% and 45% of efficacy of the full 3 do
*Efficacy against anal, head and neck, penile cancers is conferred through protectio83.9% and 84.9% at 25, 50, 75 and 100 years, respec-
tively; the US model predicted reductions of 62.4%,
79.1%, 83.0% and 83.6% at 25, 50, 75 and 100 years, re-
spectively. These relative reductions coefficients were
fairly comparable in a steady-state situation at 100 years
(< 10% difference), although significant differences were
present at 50 years. The US-based model was selected
for use in the present analysis as it was calibrated for theFemale
18 6 11 16 18
1 62.1 ― ― 76.0 96.3
― 76.1 76.1 ― ―
7 96.0 ― ― 98.8 98.4
― ― ― 98.8 98.4
7 96.0 ― ― ― ―
― 98.9 100.0 ― ―
nital infection to females, and vice versa.
ses, respectively.
n against infection only.
Table 3 Base-case input parameters used in the model
Parameter Values
Vaccine uptake, both sexes
Cumulative percentage of vaccine uptake (first dose) among 12-year olds 70%
Vaccine adherence (probability of second and third dose), both sexes
Percentage of individuals receiving the second dose given first dose 79.7%
Percentage of individuals receiving the third dose given second dose 63.5%
Duration of protection (years) lifelong
HPV, human papillomavirus. Values were derived from [17].
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HPV-related diseases other than cervical cancers and
genital warts) at the time of the analysis.Sensitivity analyses
Sensitivity analyses were performed around cumulative
vaccination coverage rate, ranging from 50% to 100% for
both girls-only and girls and boys vaccination strategies
(versus 70% in the base case) as well as compliance al-
ternatively assumed to be ‘perfect’, e.g. 100% (while
maintaining vaccine efficacy as its baseline value). Sensi-
tivity analysis was also performed around duration of
vaccine protection, in which a scenario of a shorter du-
ration of protection equal to 32 years was assessed in
line with the duration of protection assumed in a previ-
ously published analysis (Elbasha et al. 2010 [17]).
A final analysis was performed in which the girls-only
vaccination program with 50% vaccine coverage was
compared with the base case boys and girls vaccination
program (with 70% vaccine coverage rate assumed). This
comparative analysis was carried out to illustrate the po-
tential impact of a higher coverage rate among boys than
girls.Results
Base case analysis
Results are presented for a steady state situation: at 100
years, when maximum vaccination effect is reached.
Additional results at 50 years are provided in Table 4.
The results of the base case analysis showed that in
Europe, assuming a theoretical mean cumulative vaccin-
ation coverage rate of 70%, the introduction of a girls-
only vaccination strategy was associated with a notable
reduction in the incidence of HPV-related diseases in
both males and females in comparison with screening
alone (Table 4). With screening alone there were esti-
mated to be 288,959 annual cases of genital warts and
32,562 cases of HPV-related cancer in females, with the
corresponding figures in males being 325,722 and
15,497, respectively. Girls-only vaccination resulted in a
79% and 62% reduction in genital warts in females and
males and an 84% and 61% reduction in female andmale HPV-related cancers, respectively versus screening
alone.
The benefits associated with the introduction of a boys
and girls vaccination program were substantial, with the
greatest benefits being reported in terms of the reduced
incidence of genital warts. Vaccination of boys and girls
led to additional 35,164 and 87,900 cases of genital warts
being avoided in females and males, respectively
(Table 4). Overall, vaccination of boys and girls was pro-
jected to lead to an 89% reduction in the incidence of
genital warts in males and 91% reduction in females
compared with a strategy of screening alone. Genital
warts cases not prevented by girls-only vaccination are
thus reduced by 58% for female cases and 71% for male
cases due to extending vaccination to boys.
The benefits of vaccination of boys and girls in terms
of reducing the incidence of HPV-related carcinomas
were also considerable. HPV-related cancers in males
were reduced by 86% compared with screening alone
(2,119 versus 15,497 cases). Extending vaccination to
boys would therefore prevent an additional 3,911 male
cases compared with girls-only vaccination (65% reduc-
tion) (Figure 1). The largest absolute incremental impact
was observed for head and neck cancer where a reduc-
tion in the female and male absolute incidence from
5,015 to 1,828 cases was reported (an 88% reduction ver-
sus 67% with girls-only vaccination when compared with
baseline screening alone).
Another substantial benefit of vaccination of girls and
boys was in the incidence of male anal cancer; inclusion
of boys in a HPV vaccination program led to an 86% re-
duction in the incidence of anal cancer (63% reduction
with girls-only vaccination) in comparison with screen-
ing alone. Similarly, the vaccination of girls and boys
was associated with a 68% reduction in the incidence of
penile cancer, versus screening alone (compared with an
18% reduction with girls-only vaccination versus scree-
ning alone).
The vaccination of girls and boys would also lead to a
benefit in terms of additional disease prevention among
women as a consequence of indirect protection. In terms
of the incidence of HPV-related cancer in women, in the
base case analysis girls-only vaccination was associated
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84% versus screening alone; however, gender-neutral
vaccination increased this figure to 90%. Overall, in
females in the absence of vaccination there were 32,562
cases of HPV-related carcinomas, girls-only vaccination
reduced this figure to 5,217 cases, but vaccination of
girls and boys reduced the incidence of HPV-related car-
cinoma even further to 3,155 cases per year (Table 4).
Extending vaccination to boys and girls would there-
fore have the potential to reduce the HPV-related cancer
burden in males by 65% versus girls-only vaccination.
Due to indirect protection (herd immunity), vaccination
of boys would allow a further reduction of female HPV-
related cancer cases (2,062, 40%).
Sensitivity analyses
Sensitivity analyses were restricted to parameters previ-
ously shown to be key drivers of epidemiological out-
comes, i.e. vaccine coverage rates and the duration of
protection (Elbasha, 2010 [17]). Varying vaccine cover-
age rates and duration of vaccine protection over time
resulted in a notable variation in terms of the reduction
in HPV-related disease burden (Table 5). In a scenario in
which the vaccine coverage is 50% (scenario B) instead
of 70% for boys and girls vaccination (while maintaining
lifelong protection), 6,400 female and male carcinomas
are not prevented (versus 70% coverage). Indeed, in sce-
nario B fewer carcinomas cases would be avoided in
comparison with the base case girls-only vaccinationTable 4 Incremental benefit of a boys and girls vaccination st








At 50 years At 10
Female Genital warts 288,959 227,388 22
Cervical cancer 23,254 13,848 19
Vulvar cancer 2,702 873 2
Vaginal cancer 1,146 406
Anal cancer 2,929 821 2
Head/neck cancer 2,531 701 2
Total cancers 32,562 16,649 27
Male Genital warts 325,722 202,671 20
Penile cancers 1,091 93
Anal cancers 1,699 313 1
Head/neck cancers 12,707 2,555 8
Total cancers 15,497 2,961 9
Female + Male Genital warts 614,681 430,059 43
Total cancers 48,059 19,610 36
GNV, gender-neutral vaccination (boys and girls vaccination); HPV, human papillom(Figure 2 and Figure 3). Conversely, increasing the
coverage rate from 70% (base-case) to 90% (scenario C)
would lead to an additional 3,453 carcinoma cases
avoided across both genders. Sensitivity analysis also
show that the waning effect (i.e. assuming 32-year long
duration of protection instead of lifetime) has a consi-
derable influence. Between 5,653 and 10,815 carcinoma
cases (female and male) would not be prevented com-
pared with base case boys and girls vaccination, depend-
ing on the level of coverage rate assumed (Table 5). The
analysis also shows that the expected incremental benefit
of vaccinating both boys and girls is the greatest in sce-
narios in which vaccine coverage rates in girls are low
(Figure 3).
In a scenario in which a vaccine efficacy of 100% was
assumed (all other inputs were maintained at baseline
values), a 69% decrease in male HPV-related carcinomas
(minus 10,644 cases versus screening alone) would be
achieved with a girls-only vaccination program, whereas
a 61% reduction would occur in the base case girls-only
vaccination (minus 9,467 cases versus screening only at
steady state). When focusing on the impact of girls-only
vaccination on cervical cancer, reductions of 85% and
86% were estimated in the base case and 100% vaccine
efficacy scenarios, respectively. Extending vaccination to
boys assuming a 100% vaccine efficacy would lead to a
96% reduction in the remaining burden in both male
and female carcinomas (versus screening alone) com-
pared with an 89% reduction assuming base case vaccinerategy against HPV 6,11,16,18 vs. girls-only vaccination
ears; results from base case analysis)
f cases
ls only
Incremental number of cases
avoided due to GNV
(vs. girls only)
Relative reduction in
remaining burden: GNV vs.
girls only (%)
0 years At 50 years At 100 years At 50 years At 100 years
8,724 34,936 35,164 −56.7 −58.4
,728 958 1,362 −10.2 −38.6
,286 67 157 −3.7 −37.8
981 31 66 −4.2 −39.9
,330 80 258 −3.8 −43.0
,020 67 220 −3.7 −43.0
,345 1,203 2,062 −7.6 −39.5
2,587 85,740 87,900 −69.7 −71.4
197 156 542 −15.6 −60.6
,067 180 402 −13.0 −63.6
,203 1,449 2,967 −14.3 −65.9
,467 1,784 3,911 −14.2 −64.9
1,311 120,676 123,064 −65.4 −67.1














65% reduction of remaining














40% reduction of remaining 
cancer burden in females
Cervical cancer































Figure 1 Annual number HPV 16/18 related carcinoma cases among males and females when considering a vaccination strategy of
boys and girls aged 12 versus girls only vaccination aged 12 (70% vaccine coverage rates assumed for all cohorts) - base case analysis
presented at steady-state, 100 years. The remaining annual burden of male HPV-related carcinomas is shown in the chart on the left side;
remaining burden of female HPV-related carcinomas is shown in the chart on the right hand side.
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related parameters estimates are key drivers of the
results of modeling studies.
In a scenario that assumed 100% compliance (every-
thing else being equal), girls-only vaccination would re-
duce cervical cancer burden by 91% (in comparison with
85% in the base case girls-only vaccination scenario) and
extending vaccination to boys would lead to a 91% re-
duction of male HPV-related carcinomas (versus an 86%
reduction in the base case girls-only vaccination sce-
nario). A final sensitivity analysis aimed at exploring the
leveraging effect of the introduction of HPV vaccination
for boys on the vaccine uptake among girls was per-
formed. It may be expected that vaccinating boys may
increase the coverage rate among girls. When the base-
case boys and girls vaccination (70% coverage) is com-
pared with girls-only vaccination (50% coverage), such a
“snow-ball” effect would prevent an estimated 13,019
carcinoma cases (half for each gender) and more than
160,000 cases of genital warts (Figure 3).
Discussion
The results of the present analysis indicate that, assu-
ming overall vaccination coverage of 70%, the vaccin-
ation of both girls and boys using the quadrivalent HPV
vaccine was associated with notable incremental clinical
benefits versus a strategy of girls-only vaccination. Thisis in contrast to other modeling studies, which con-
cluded that the incremental impact of vaccinating boys
was limited [18,19,21]. According to the present analysis,
vaccination of boys and girls led to a 40% reduction in
the incidence of HPV-related cancers and 58% reduction
in the incidence of genital warts in females versus girls-
only vaccination. Similarly, in males the incremental
benefits associated with vaccination of boys and girls
were a 65% reduction in the incidence of HPV-related
carcinoma, including a 66% reduction in the incidence
of HPV-related head and neck cancer and a 71% reduc-
tion in genital warts. Moreover, the incremental benefit
of vaccinating both boys and girls was greatest in
instances where the vaccination coverage rates in girls
are sub-optimal, a finding that concurs with the findings
from other modeling studies [18,19,21].
Differences in model structure and assumptions related
to the natural history of HPV transmission and develop-
ment of the disease, as well as differences in clinical out-
comes, (used to assess the population-level clinical be-
nefits) make direct comparisons between the outcomes of
different models challenging. For example, Brisson et al.
present their results in terms of HPV infection. They re-
port the relative reduction in HPV-16/18 prevalence at
equilibrium compared with no vaccination and the relative
reduction in the incidence of vaccine-type infections over
the first 70 years after the start of the vaccination, whereas
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related diseases incidence rather than infections at equilib-
rium (100 years) [19]. Equilibrium was also assumed to be
achieved at different time points across studies (from 50
years in Smith et al. to 100 years in the present study in
line with previous work) [17,18]. Given the different
approaches used in the current analysis and that of previ-
ously published analyses a detailed structural analysis and
comparison of each model would identify the key differ-
ences in terms of underlying epidemiology, assumptions
used and drivers of results. However, a detailed compari-
son of different available HPV models is beyond the scope
of the present analysis.
Whilst previous modeling studies have focused on the
reduction of the incidence of HPV infections and cer-
vical cancer, data relating to the impact on vulvar, vagi-
nal, penile, anal and head and neck cancer have until
now been lacking. While girls-only vaccination would
substantially reduce the incidence of HPV-related cancer
in females and in some extent in males (due to herd
immunity), vaccination of boys in addition to girls is
associated with a substantial incremental benefit for
both males (direct benefits) and females (indirect benefits).
Indeed, in our base case, the estimated proportion of
the maximum possible vaccine-conferred benefit to
males (in terms of male HPV-related carcinomas) fromTable 5 Sensitivity analysis: number of cases avoided for the
boys and girls base case analysis (vaccine coverage rate: 70%
reductions
Absolute reduction (increase) of remaining cases (n) versus base cas
vaccination strategy
Duration of protection Lifetime 32 yea
Coverage rate 50% 90% 70% 50%
Vaccination strategy B C D E
Female Genital warts 40,271 −24,568 68,313 108,00
Cervical cancer 3,212 −1,692 5,685 8,853
Vulvar cancer 337 −158 568 925
Vaginal cancer 139 −63 236 388
Anal cancer 357 −192 598 978
Head/neck cancer 305 −163 504 832
Total cancers 4,351 −2,269 7,591 11,976
Male Genital warts 49,534 −34,444 77,279 122,84
Penile cancers 155 −124 237 358
Anal cancers 225 −129 351 576
Head/neck cancer 1,669 −931 2,636 4,331
Total cancers 2,050 −1,184 3,224 5,264
Female + Male Genital warts 89,805 −59,013 145,592 230,85
Total cancers 6,400 −3,453 10,815 17,240
HPV, human papillomavirus.
Negative values mean a reduction of the number of HPV burden of the disease and
boys and girls vaccination strategy (GNV).gender-neutral vaccination, which would be achieved by
a girls-only vaccination program, was as high as 71%.
Nevertheless, this proportion may be reduced to 64% in
scenarios assuming a lower vaccine coverage among girls
(50%), and even further if a lower coverage rate occurred
in conjunction with a waning effect (32 year long du-
ration of protection). Such proportions refer to “propor-
tional benefit achieved” as described by Smith et al.,
which primarily applied these calculations in terms of
HPV-16 infection incidence data. The results suggest
that in Europe, vaccination of boys and girls could pre-
vent over 5,500 cases of HPV-related cancer annually
(versus girls-only vaccination). Here, we present the
number of HPV cancer cases avoided that are specifically
due to HPV types 16 and 18. A previous analysis in the
UK setting comparing quadrivalent and bivalent HPV
vaccines assumed both vaccines provided some cross-
protection against carcinomas caused by non-vaccine
HPV subtypes. If vaccination does provide some cross
protection for non-vaccine HPV types then potential
clinical benefits estimated here may be conservative.
However, research on cross-protection is currently on-
going and as such it was not included in this analysis
[24].
With regard to the impact on genital warts, vacci-
nation of boys and girls would reduce the incidence ofdifferent boys and girls vaccination strategies versus
, lifelong protection) and the corresponding relative
e GNV Relative reduction (increase) of remaining cases (%)
versus base case GNV vaccination strategy
rs
90%
F B C D E F
9 38,674 160.6 −98.0 272.5 430.8 154.3
3,092 148.4 −78.2 262.7 409.1 142.9
285 130.3 −61.2 219.5 357.4 110.1
116 140.3 −63.7 238.2 392.2 117.6
300 104.6 −56.3 175.1 286.4 88.0
250 104.6 −55.9 173.0 285.3 85.6
4,044 137.9 −71.9 240.6 379.6 128.2
6 43,104 140.6 −97.8 219.3 348.6 122.3
130 44.1 −35.2 67.3 101.6 37.0
173 98.0 −56.0 152.7 250.6 75.1
1,306 108.6 −60.6 171.5 281.8 85.0
1,609 96.7 −55.9 152.2 248.5 75.9
5 81,778 148.9 −97.9 241.4 382.8 135.6
5,653 121.4 −65.5 205.1 326.9 107.2









































Figure 2 Estimated annual remaining burden over the years 2012–2112 of HPV-related diseases when vaccinating 12-year old boys
and girls versus girls only vaccination aged 12 (cumulative vaccination coverage rate 70%, lifetime duration of protection). Remaining
burden of HPV-related cases by subgroup of HPV conditions overtime under either girls-only vaccination or boys and girls vaccination. x-axis : years
after implementation; y-axis: remaining number of cases. (A)-male genital warts; (B)- HPV 16/18 related male cancers. Black dotted-lines represent the
base line (screening only). Pink lines represent the remaining cases in case of girls-only vaccination. Blue lines represent the remaining cases in case of
boys and girls vaccination. Percents given are the relative reduction of incident cases compared with screening alone for a given year: either at 50
years or at 100 years. Over 50 years, (Area Under the Curve), vs. screening only were 32,788 HPV 16/18-related cancers cases and 7.0 million HPV6/11-
related genital warts cases, respectively, which would have been avoided in males when vaccinating girls only. Additionally, 52,354 HPV 16/18-related
cancers and 9.8 million HPV6/11-related genital warts cases would be avoided when vaccinating boys and girls.
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http://www.biomedcentral.com/1471-2407/13/10genital warts by approximately 90%, which would likely
lead to considerable economic benefits in terms of costs
and resource use, indeed the economic burden of genital
warts has been reported as being comparable to that of
HPV related cancer and it has also been estimated that
currently up 10% of visits to sexual health clinics are
due to genital warts [14]. Additionally, the current ana-
lysis does not capture benefits in terms of quality of life
or costs savings, which are also likely to be substantial.
Previous studies have shown that vaccine coverage in
girls is a key driver of outcomes in both males and
females [18,19]. Vaccine efficacy as well as compliance
were also shown to be of particular interest when asses-
sing the results. In Europe, vaccine coverage varies
widely depending on setting due to differences in vacci-
nation policy and modes of implementation (e.g. school
based, invitation-based or available on request, and
whether a catch-up program is in place for adolescent
girls and young women). Countries with school-basedvaccination programmes such as the UK have coverage
rates of 80–90%, but school based programs only cover
13% of young women living in the EU. In settings where
vaccination is administered on demand, such as France
and Germany coverage rates are around 50%. In addition
to substantial variations in vaccine coverage there are
also marked differences across Europe with regard to
uptake of cervical screening, which again is influenced
by policies implemented on a national level. The propor-
tion of women screened has been found to vary notably
according to both age group and setting. For example, in
Norway, Sweden and The Netherlands screening rates
are high due to organized population-based programs,
whereas in many other EU countries cervical screening
remains opportunistic (e.g. France, Germany) with un-
equal access to screening and lower coverage or vari-
ation from one region to another (e.g. Spain, Italy) [25].
The results of the current analysis, together with the














Additional number of female and male carcinoma cases avoided
Delta










Figure 3 Deterministic sensitivity analysis: impact of vaccinating boys and girls versus girls only vaccination† when considering the
reduction of remaining burden of female and male carcinomas cases and percentage of relative variation versus base case analysis‡.
GNV, gender-neutral vaccination (boys and girls vaccination). †: same coverage rate and duration of protection are assumed to be applied to boys and
girls vaccination and girls only vaccination. ‡: boys and girls vaccination (cumulative vaccination coverage rate 70%, lifetime duration of protection).
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http://www.biomedcentral.com/1471-2407/13/10vaccination of boys and girls would be associated with the
greatest benefit in settings where vaccine uptake among
girls is low such as those countries that do not have a na-
tionally coordinated vaccination program for females
[18,26]. However, whether it is more feasible/more effi-
cient to implement a strategy of vaccinating both boys and
girls or increase vaccine uptake among girls only is an im-
portant policy decision that needs to be addressed on a
national level given the variety of different vaccine imple-
mentation strategies (and hence coverage rates) in place
across Europe. Indirect protection (herd immunity) in
males is strongly dependent on vaccine coverage in
females so the vaccination strategy used and coverage rate
achieved is a key factor in determining the incremental
benefit of the vaccination of boys at a national level.
Additionally, ethical considerations are warranted regard-
ing the type of vaccination program implemented (e.g. a
consumer based approach versus a partially or fully sub-
sided voluntary program versus compulsory vaccination).
The analysis presented here is associated with both
strengths and limitations. Limitations of the current ana-
lysis include the fact that it does not consider the inci-
dence of precancerous states such as cervical, vulvar,
vaginal, anal or penile intraepithelial neoplasia, or cap-
ture temporal trends in HPV-related disease, such as the
increasing incidence of head and neck cancer and anal
cancer. Moreover, there is substantial uncertainty in the
proportion of head and neck carcinoma attributable to
HPV, which may be a contributing factor in the diffe-
rences in the magnitude of clinical benefit reportedacross different studies. The present analysis was based
on a proportion of 19% of head and neck cancers being
attributable to HPV-16/18. This figure might be overes-
timated even if it is in line with estimates assumed in
another recent modeling study by Smith et al. 2011 [18].
Given the magnitude of the burden of the disease of this
subset of HPV-related conditions among males in par-
ticular, this is an area that potentially warrants further
investigation.
Additionally, this analysis does not consider the quality
of life benefit associated with the reduction in the inci-
dence of HPV-related disease, which is also likely to be
substantial. A further limitation of this analysis is that it
is an exploratory analysis that presents mean findings re-
lating to Europe as a whole and also that the model used
here and applied to the European setting was based on a
US-based dynamic transmission model with input data
derived from the US setting, which may potentially limit
its applicability to the European setting. In particular,
the US-base case scenario (screening alone) is supposed
to be consistent with what would be a European base
case (screening alone). This is a strong underlying as-
sumption given the specificities of screening implemen-
tation in the US and Europe in particular, in addition it
is assumed that sexual behavior patterns and the age-
structure of the population is similar between settings.
Another limitation concerns the structure of the model
in that it consists of a number of independent submo-
dels (according to disease type), and incorporates the
assumption that only subjects who are at risk of
Marty et al. BMC Cancer 2013, 13:10 Page 11 of 12
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As such, this means the transmission dynamics for
female-only conditions (cervical, vaginal and vulvar can-
cer) are different from those where both males and
females may be affected (head and neck and anal cancer)
and from the male only penile cancer submodel. In
addition, within Europe there are wide variations in vac-
cine uptake rates, screening coverage, HPV prevalence
and transmission rates, and as shown here, vaccination
uptake rates are a key driver of outcomes.
One of the key strengths of the analysis is that it
assesses the benefits of male vaccination in all carci-
nomas that have an established causal link with HPV 6,
11, 16 and 18 whereas many previous analyses have fo-
cused primarily on the impact of vaccination in terms of
cervical cancer incidence. The current analysis incorpo-
rates an extended number of HPV-related disease end-
points including subtypes of head and neck cancer and
as such reflect the potential maximum clinical benefits
that could be gained from different HPV vaccination
scenarios (in comparison with a number of previous
analyses that have focused largely on cervical cancer and
genital warts only). It is also likely that the potential
maximum clinical benefit reported in the current ana-
lysis would have been even greater if pre-cancerous
states had been included in the analysis. Another
strength is that this is the first analysis to present the po-
tential public health impact at EU level of vaccinating
boys and girls.
Further country-specific analyses that fully deal with
uncertainty are required in order to guide policy deci-
sions relating to the incremental benefits of vaccination
of boys and girls. Until such data are available on a
country by country basis, a pooled European-wide ana-
lysis may provide useful estimates, as well as serving as a
valuable comparator for such analyses.Conclusions
This analysis is the first to assess the impact of gender-
neutral vaccination in Europe; however, as noted
country-specific analyses that take into account national
vaccination policies, coverage rates and socio-ethical
implications of different strategies may be required to
assess the impact of gender-neutral vaccination at a
national level.
These European-level results suggest that vaccination
of boys and girls against HPV 6, 11, 16 and 18 would be
associated with a marked incremental benefit in terms of
a reduction in the incidence of HPV-related cancers and
genital warts in males (31% to 77% and 30% to 99%,
respectively) and would help decreasing the remaining
burden of both HPV-related cancers and genital warts in
females (14% to 68% and 21% to 98%, respectively).These figures represent the maximal potential benefit
associated with vaccination due to the incorporation of
an extended range of HPV-related cancers in the model,
but may warrant updating in future analyses owing the
current uncertainty that exists with regard to the pro-
portion included cancers, in particular head and neck
cancer that can be attributed directly to HPV.
Additionally, the incremental benefit is likely to be
greatest in settings where vaccine coverage rates in
females are not the highest. In addition to the clinical
benefit, the notable reduction in the incidence of HPV-
related disease is also likely to be associated with a sub-
stantial reduction in the economic burden associated
with HPV-related cancers and genital warts.
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